{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 68,
        "end": 102
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 93,
        "end": 102
      }
    },
    {
      "id": "T3",
      "obj": "Disease",
      "span": {
        "begin": 130,
        "end": 160
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 130,
        "end": 135
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 68,
        "end": 72
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 68,
        "end": 121
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "16144943_13",
  "text": "CONCLUSIONS : These preclinical findings support the development of SAHA in combination with docetaxel and/or trastuzumab against Her-2 -amplified breast cancer ."
}
